(Q39459263)

12 September 2017

1 reference

title

Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine (English)

1 reference

12 September 2017

1 reference

1 reference

N Thatcher

1

1 reference

PubMed ID

9166093

12 September 2017

P Hopwood

series ordinal

2

1 reference

PubMed ID

9166093

12 September 2017

H Anderson

series ordinal

3

1 reference

12 September 2017

1 January 1997

1 reference

European Journal of Cancer

12 September 2017

1 reference

12 September 2017

33 Suppl 1

1 reference

12 September 2017

S8-13

1 reference

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Quality of life in cancer: definition, purpose, and method of measurement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Safety profile of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Nitrogen mustard and the steroid hormones in the treatment of inoperable bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Alkylating agents in bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Comparison of treatment policies in inoperable bronchial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Treatment of inoperable carcinoma of bronchus

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Symptomatic treatmentversus combination chemotherapy for patients with extensive non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900336-X

7 January 2021

10.1016/S0959-8049(96)00336-X

Identifiers

DOI

1 reference

12 September 2017

1 reference

PubMed ID

9166093